Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat‐PAD, the first in a new class of synthetic peptide immuno‐regulatory epitopes | Zendy

Hafner Roderick | Zendy; Couroux Peter | Zendy; Armstrong Kristen | Zendy; Patel Deepen | Zendy; Larche Mark | Zendy; Haumann Brett | Zendy

Open Access

Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat‐PAD, the first in a new class of synthetic peptide immuno‐regulatory epitopes

Author(s) -

Hafner Roderick,

Couroux Peter,

Armstrong Kristen,

Patel Deepen,

Larche Mark,

Haumann Brett

Publication year - 2013

Publication title -

clinical and translational allergy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.979

H-Index - 37

ISSN - 2045-7022

DOI - 10.1186/2045-7022-3-s2-o7

Subject(s) - medicine , placebo , nose , allergy , allergen , surgery , immunology , pathology , alternative medicine

Background Treatment with Cat-PAD (also known as ToleroMune Cat, the first in a new class of synthetic peptide immuno-regulatory epitopes), in an Environmental Exposure Chamber (EEC) model of cat allergy showed a persistent treatment effect one year [1] and two years [2] after administration of only 4 injections over 12 weeks. Here we report the differences in Total Nasal Symptom Scores (TNSS) between Cat-PAD treatment arms and placebo two years after treatment started.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research